Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,403,597 shares, an increase of 87.5% from the September 15th total of 1,281,818 shares. Currently, 1.5% of the company’s shares are short sold. Based on an average trading volume of 464,319 shares, the days-to-cover ratio is currently 5.2 days.
Entera Bio Trading Down 2.3%
Shares of ENTX stock traded down $0.07 on Friday, hitting $2.71. 366,096 shares of the stock were exchanged, compared to its average volume of 1,006,757. Entera Bio has a fifty-two week low of $0.91 and a fifty-two week high of $4.20. The business has a 50-day moving average of $2.89 and a 200 day moving average of $2.01. The firm has a market capitalization of $470.45 million, a P/E ratio of -7.73 and a beta of 1.40.
Entera Bio (NASDAQ:ENTX – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). As a group, research analysts forecast that Entera Bio will post -0.40 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts recently issued reports on the stock. Lifesci Capital started coverage on shares of Entera Bio in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Entera Bio in a research report on Tuesday, September 22nd. They set an “overweight” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday. Guggenheim started coverage on Entera Bio in a report on Thursday, September 24th. They issued a “buy” rating and a $11.00 price target for the company. Finally, Wall Street Zen raised Entera Bio to a “sell” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.60.
Institutional Investors Weigh In On Entera Bio
A hedge fund recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP boosted its position in shares of Entera Bio Ltd. (NASDAQ:ENTX – Free Report) by 51.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 205,542 shares of the company’s stock after acquiring an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned 0.42% of Entera Bio worth $228,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 14.11% of the company’s stock.
About Entera Bio
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.
Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.
Featured Articles
- Five stocks we like better than Entera Bio
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
